August 6, 2019 - 10:00 AM
August 6, 2019 - 11:15 AM
Assessment of Needs
The IAS–USA offers this state-of-the-art activity as part of a nationwide continuing medical education (CME) effort for physicians on the evolving challenges of managing HIV disease. Risk for brain injury in patients with HIV infection and adherent to combination therapies persists despite suppression of plasma viremia. Among older patients, data support progressive atrophy, with abnormalities in brain integrity linked to the degree of systemic inflammation. This webinar will review current knowledge related to symptomatic cognitive impairment in patients who are virally suppressed. This webinar will also review the challenges of differentiating HIV-related cognitive impairment from Alzheimer’s disease among older people living with HIV. This diagnostic dilemma has emerged as one of the most challenging and pertinent clinical issue of our of the cART era.
On completion of this webinar, learners will be able to:
- Gain an appreciation for the characteristics and correlates of cognitive impairment in the current era
- Understand the challenges in distinguishing HIV-related cognitive impairment from that of Alzheimer’s disease
- Recognize possible directions for care among individuals with mild cognitive symptoms in the setting of HIV
Who Should Attend
This advanced webinar is designed for clinical decision makers who are actively involved in HIV care and research.
This activity is also relevant for registered nurses, PharmDs, and other health professionals.
Individual registration is required, even if you are viewing as a group, in order to receive CME credit or a certificate of participation.
Registration closes on Monday, August 5, 2019, 4:00 PM (PT).
Certificates will be available after the completion of the evaluation and claim form.
For more information or questions, please contact the registration department at registration“at”iasusa.org or 415-544-9400.
Conflicts of Interest
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
The ACCME defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.”
Dr Valcour has served as a consultant to Merck and ViiV Healthcare. (Updated 08/06/19)
Dr Spudich has no relevant financial affiliations to disclose. (Updated 08/06/19)
CME Planner and Reviewer
Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 08/06/19)
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 1.25 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 1.25 contact hours (0.125 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time. The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN # 0761-9999-18-185-L02-P
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc.
Merck & Co, Inc.
Additional support has been provided by
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at registration“at”iasusa.org or 415-544-9400.